Read a GLP‑1 drug labeling update

On November 9, 2026, the U.S. FDA announced required GLP‑1 receptor agonist labeling changes concerning the potential risk of NAION, a rare optic nerve disorder.

What to check after reading

Look up the jurisdiction, affected products, label sections being updated, and how the source describes the risk.

Source

U.S. FDA drug safety communication ↗

Calendar dates show when a case was added or scheduled. For event dates, check the original source.